Janux Therapeutics' innovative cancer treatment shows promise in reducing side effects and improving patient outcomes, but stock risks remain. See more on JANX.

On Friday, Amgen Inc (AMGN) stock saw a decline, ending the day at $283.61 which represents a decrease of $-12.32 or -4.16% from the prior close of $295.93. The stock opened at $291.5 and touched a ...

In the ongoing case of Carefirst of Maryland Inc. v. Johnson & Johnson, the plaintiffs successfully overcame a motion to ...

Analyzing Amgen's stock drop, management's response, and potential for growth in GLP-1 candidate MariTide in a volatile ...

Amgen (AMGN) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

The Dow Jones Industrial Average is declining Monday morning with shares of Nike and NVIDIA Corp. delivering the stiffest headwinds for the index. The Dow was most recently trading 111 points, or 0.3% ...

Northern Irelands Tom McKibbin claimed the last of the 10 PGA Tour cards on offer via the Race to Dubai rankings and will ...

We recently compiled a list of the 10 Best Immunotherapy Stocks to Buy Now. In this article, we are going to take a look at ...

Barclays analyst Carter Gould maintained a Buy rating on Eli Lilly & Co (LLY – Research Report) today and set a price target of $975.00.